Breast Cancer Diagnostics Market: Introduction
According to the report, the global breast cancer diagnostics market was valued at ~US$ 4.8
Bn in 2018 and is projected to expand at a high CAGR during the forecast period. Breast cancer
is a type of cancer that starts in the breast, where the cells grow out of control. The breast
cancer cells are formed in the lobules or ducts of the breast. It can also occur in the fatty tissue
or the fibrous connective tissue of the breast. Breast cancer is the most common form of cancer
among women across the globe. Older women are at higher risk of developing breast cancer.
Breast cancer does not show any symptoms in the early stages. Different types of breast cancer
have different symptoms. The common symptoms of breast cancer are breast lump, abnormal
thickening of breast tissues, changes in size, shape, and appearance of the breast; changes in
the skin over the breast, swelling in all parts of breast, inverted nipple, and peeling & scaling of
skin on nipple. Breast cancer is primarily categorized into invasive breast cancer and non-
invasive breast cancer. Invasive breast cancer is the most common form and accounts for
about 80% of total breast cancer diagnosed globally.
Breast cancer can be diagnosed with different imaging tools such as mammography, breast
ultrasound systems, MRI scans, breast biopsy, and molecular diagnostics. Advancements in
breast cancer diagnosis and increase in awareness about breast cancer in developed countries
have led to the increased survival rates. Technological advancements in breast imaging, tissue
biopsies, and molecular testing are likely to enable early detection and screening of breast
cancer. The growth of the global breast cancer diagnostics market can also be attributed to the
rise in prevalence of breast cancer across the globe, technological advancements & new
product development, and increase in the geriatric population.
North America dominated the global breast cancer diagnostics market in 2018 and the trend is